# EDGAR Filing Document

**Accession Number:** 0002117222
**File Stem:** 0002117222-26-000004
**Filing Date:** 2026-3
**Character Count:** 8973
**Document Hash:** 9291a451cd7568f35fede3a8edcefd22
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002117222-26-000004.hdr.sgml**: 20260317

**ACCESSION NUMBER**: 0002117222-26-000004

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260315

**FILED AS OF DATE**: 20260317

**DATE AS OF CHANGE**: 20260317

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ratz Andrew
- **CENTRAL INDEX KEY:** 0002117222

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-22705
- **FILM NUMBER:** 26763848

**MAIL ADDRESS:**
- **STREET 1:** 6027 EDGEWOOD BEND COURT
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEUROCRINE BIOSCIENCES INC
- **CENTRAL INDEX KEY:** 0000914475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330525145
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6027 EDGEWOOD BEND COURT
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 617-7600

**MAIL ADDRESS:**
- **STREET 1:** 6027 EDGEWOOD BEND COURT
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

## Ex-24

```

POWER OF ATTORNEY

(For Executing Forms 3, 4, and 5):

Know all by these presents, that the undersigned hereby constitutes
and appoints each of Kyle W. Gano, Matthew C. Abernethy, and
Darin Lippoldt of Neurocrine Biosciences, Inc. (the "Company"),
signing individually, the undersigned's true and lawful attorneys-in-fact
and agents to:

(1) prepare, execute in the undersigned's name
and on the undersigned's behalf, and submit to the Securities and Exchange
Commission (the "SEC") Forms 3, 4 and 5 (including any amendments thereto)
in accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), and the rules thereunder in the undersigned's
capacity as an officer, director or beneficial owner of more than 10% of a
registered class of securities of the Company;

(2) do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to execute such Forms 3, 4 or 5
(including amendments thereto) and timely file such forms with the
SEC and any stock exchange or any similar authority; and

(3) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required of the undersigned,
it being understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney shall be
in such form and shall contain such terms and conditions as such attorney-
in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents
and purposes as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact,
and their substitutes, in serving in such capacity at the request of
the undersigned, are not assuming (nor is the Company assuming)
any of the undersigned's responsibilities to comply with Section 16
of the Exchange Act.

This Power of Attorney shall remain in full force and effect until
the earliest to occur of (a) the undersigned is no longer required to
file Forms 3, 4 and 5 with respect to the undersigned's holdings of
and transactions in securities issued by the Company, (b)
revocation by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed
by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of the date written below.

Date:  23-February-2026
/s/ Andrew Ratz
Name: Andrew Ratz

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ratz Andrew<br><sub>(Last) (First) (Middle)</sub><br>6027 EDGEWOOD BEND CT.<br><sub>(Street)</sub><br>SAN DIEGO, CA 92130<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>NEUROCRINE BIOSCIENCES INC [ NBIX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-15 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Technical Operations Off_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 1018 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 3997 | <sup>(2)</sup> | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 5640 | <sup>(2)</sup> | D |  |
| Incentive Stock Option | <sup>(4)</sup> | 2035-02-03 | Common Stock | 2664 | $150.10 | D |  |
| Non-Qualified Stock Option | <sup>(4)</sup> | 2035-02-03 | Common Stock | 17724 | $150.10 | D |  |
| Incentive Stock Option | <sup>(5)</sup> | 2036-02-13 | Common Stock | 805 | $124.12 | D |  |
| Non-Qualified Stock Option | <sup>(5)</sup> | 2036-02-13 | Common Stock | 31348 | $124.12 | D |  |

---

### Footnotes:

(1) Represents Restricted Stock Units (RSUs) remaining outstanding as of March 15, 2026. The RSU vested and settled as to 1/4 of the total units on February 3, 2026. The remaining RSUs vest annually at 1/4 of the total units subject to the award vesting on each of February 3, 2027, February 3, 2028, and February 3, 2029.

(2) Each RSU represents a contingent right to receive one share of the Issuer's common stock.

(3) The RSUs will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

(4) Represents option of which 1/4th of the shares underlying the option became vested and exercisable on February 3, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

(5) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

**Signature:** /s/ Darin Lippoldt, Attorney-in-Fact  
**Date:** 2026-03-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**